{"Symbol": "CGEN", "AssetType": "Common Stock", "Name": "Compugen Ltd", "Description": "Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; BAY 1905254, a therapeutic antibody targeting ILDR2, which is in Phase I clinical study in patients with solid tumors; and COM902, a therapeutic antibody targeting TIGIT. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics for antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "Healthcare", "Industry": "Biotechnology", "Address": "Building D, Holon, Israel, 5885849", "FullTimeEmployees": "61", "FiscalYearEnd": "December", "LatestQuarter": "2020-06-30", "MarketCapitalization": "1482724608", "EBITDA": "-27295000", "PERatio": "None", "PEGRatio": "0", "BookValue": "1.566", "DividendPerShare": "None", "DividendYield": "0", "EPS": "-0.453", "RevenuePerShareTTM": "0", "ProfitMargin": "0", "OperatingMarginTTM": "0", "ReturnOnAssetsTTM": "-0.1773", "ReturnOnEquityTTM": "-0.3265", "RevenueTTM": "0", "GrossProfitTTM": "0", "DilutedEPSTTM": "-0.37", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "0", "AnalystTargetPrice": "19.75", "TrailingPE": "0", "ForwardPE": "0", "PriceToSalesRatioTTM": "0", "PriceToBookRatio": "10.5965", "EVToRevenue": "0", "EVToEBITDA": "0", "Beta": "2.7593", "52WeekHigh": "19.9", "52WeekLow": "3.6373", "50DayMovingAverage": "16.4042", "200DayMovingAverage": "13.1253", "SharesOutstanding": "82694200", "SharesFloat": "165117181", "SharesShort": "6418532", "SharesShortPriorMonth": "5844181", "ShortRatio": "4.47", "ShortPercentOutstanding": "0.07", "ShortPercentFloat": "0.107", "PercentInsiders": "0.183", "PercentInstitutions": "31.243", "ForwardAnnualDividendRate": "0", "ForwardAnnualDividendYield": "0", "PayoutRatio": "0", "DividendDate": "None", "ExDividendDate": "None", "LastSplitFactor": "None", "LastSplitDate": "None"}